Cargando…

[(18)F]FDG-PET/CT in patients with bacteremia: Clinical impact on patient management and outcome

Bacteremia is the presence of viable bacteria in the bloodstream, a complicated and potentially dangerous systemic medical condition that may range from asymptomatic and clinically relatively indolent cases to more severe bloodstream infection (BSI) and ultimately life-threatening septic shock with...

Descripción completa

Detalles Bibliográficos
Autor principal: Hess, Søren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095558/
https://www.ncbi.nlm.nih.gov/pubmed/37064040
http://dx.doi.org/10.3389/fmed.2023.1157692
_version_ 1785024112359374848
author Hess, Søren
author_facet Hess, Søren
author_sort Hess, Søren
collection PubMed
description Bacteremia is the presence of viable bacteria in the bloodstream, a complicated and potentially dangerous systemic medical condition that may range from asymptomatic and clinically relatively indolent cases to more severe bloodstream infection (BSI) and ultimately life-threatening septic shock with fatal outcome. BSI is classified as simple (bacteremia only) or complex (BSI with metastatic spread), and the morbidity is higher in the latter, probably due to insufficient eradication. Treatment of simple BSI is usually short-term antibiotic courses, whereas complex BSI with metastatic foci requires more advanced treatment including long-term antibiotics or invasive drainage to gain infection control. Thus, identifying metastatic infection has an important clinical impact but remains a challenge; only half of the patients progress to complex BSI, and many patients present without relevant signs or symptoms, so imaging is pivotal. This review summarizes the potential role and recommendations of [(18)F]FDG-PET/CT in BSI, based on the relatively sparse and heterogeneous literature. [(18)F]FDG-PET/CT should be considered in suspected complex BSI, in patients at high risk of metastatic spread, and in BSI in ICU patients. [(18)F]FDG-PET/CT has an impact on patient management, treatment strategy, and patient outcome, mainly by directing the diagnostic process toward more specific diagnostics or by modifying treatment regimens resulting in reduced relapse rates and reduced mortality. Finally, a negative scan may obviate the need for further workup.
format Online
Article
Text
id pubmed-10095558
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100955582023-04-13 [(18)F]FDG-PET/CT in patients with bacteremia: Clinical impact on patient management and outcome Hess, Søren Front Med (Lausanne) Medicine Bacteremia is the presence of viable bacteria in the bloodstream, a complicated and potentially dangerous systemic medical condition that may range from asymptomatic and clinically relatively indolent cases to more severe bloodstream infection (BSI) and ultimately life-threatening septic shock with fatal outcome. BSI is classified as simple (bacteremia only) or complex (BSI with metastatic spread), and the morbidity is higher in the latter, probably due to insufficient eradication. Treatment of simple BSI is usually short-term antibiotic courses, whereas complex BSI with metastatic foci requires more advanced treatment including long-term antibiotics or invasive drainage to gain infection control. Thus, identifying metastatic infection has an important clinical impact but remains a challenge; only half of the patients progress to complex BSI, and many patients present without relevant signs or symptoms, so imaging is pivotal. This review summarizes the potential role and recommendations of [(18)F]FDG-PET/CT in BSI, based on the relatively sparse and heterogeneous literature. [(18)F]FDG-PET/CT should be considered in suspected complex BSI, in patients at high risk of metastatic spread, and in BSI in ICU patients. [(18)F]FDG-PET/CT has an impact on patient management, treatment strategy, and patient outcome, mainly by directing the diagnostic process toward more specific diagnostics or by modifying treatment regimens resulting in reduced relapse rates and reduced mortality. Finally, a negative scan may obviate the need for further workup. Frontiers Media S.A. 2023-03-29 /pmc/articles/PMC10095558/ /pubmed/37064040 http://dx.doi.org/10.3389/fmed.2023.1157692 Text en Copyright © 2023 Hess. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Hess, Søren
[(18)F]FDG-PET/CT in patients with bacteremia: Clinical impact on patient management and outcome
title [(18)F]FDG-PET/CT in patients with bacteremia: Clinical impact on patient management and outcome
title_full [(18)F]FDG-PET/CT in patients with bacteremia: Clinical impact on patient management and outcome
title_fullStr [(18)F]FDG-PET/CT in patients with bacteremia: Clinical impact on patient management and outcome
title_full_unstemmed [(18)F]FDG-PET/CT in patients with bacteremia: Clinical impact on patient management and outcome
title_short [(18)F]FDG-PET/CT in patients with bacteremia: Clinical impact on patient management and outcome
title_sort [(18)f]fdg-pet/ct in patients with bacteremia: clinical impact on patient management and outcome
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095558/
https://www.ncbi.nlm.nih.gov/pubmed/37064040
http://dx.doi.org/10.3389/fmed.2023.1157692
work_keys_str_mv AT hesssøren 18ffdgpetctinpatientswithbacteremiaclinicalimpactonpatientmanagementandoutcome